Premium
Mammalian target of rapamycin (mTOR) inhibition does not prevent lung adenocarcinoma‐induced malignant pleural effusion
Author(s) -
Vazakidou MariaEleni,
Magkouta Sofia,
Moschos Charalambos,
Kalomenidis Ioannis
Publication year - 2014
Publication title -
respirology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.857
H-Index - 85
eISSN - 1440-1843
pISSN - 1323-7799
DOI - 10.1111/resp.12151
Subject(s) - temsirolimus , medicine , discovery and development of mtor inhibitors , malignant pleural effusion , pleural effusion , lung , adenocarcinoma , pi3k/akt/mtor pathway , vascular endothelial growth factor , pathology , cancer research , cancer , vegf receptors , apoptosis , biochemistry , chemistry
The impact of temsirolimus was investigated in a murine model of malignant pleural effusion ( MPE ) created with intrapleural injection of L ewis L ung C ancer ( LLC ) cells. Temsirolimus (1 or 20 mg/kg) did not affect the pleural fluid volume or the number of pleural tumour foci. In addition, temsirolimus did not affect vascular endothelial growth factor expression by LLC cells in vitro . In conclusion, temsirolimus did not curtail experimental lung‐adenocarcinoma‐induced MPE .